OSSIO receives FDA clearance for bone fixation technology in pediatric surgery
Click Here to Manage Email Alerts
Key takeaways:
- OSSIO announced FDA clearance of its OSSIOfiber bio-integrative bone fixation technology for use in pediatric surgery.
- The OSSIOfiber implants are indicated for use in several pediatric trauma surgeries.
OSSIO has announced FDA clearance of its OSSIOfiber bio-integrative bone fixation technology for use in orthopedic surgery for children and adolescents, according to a press release.
The OSSIOfiber implants are indicated for fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis and bone grafts in pediatric patients, according to the release.
“With this highly anticipated clearance, OSSIO enters an important segment of orthopedic surgery, adding to our expanding portfolio of OSSIOfiber implants for the fixation of bone fractures and soft tissue injuries throughout the body in various clinical scenarios – now including the treatment of fractures in children as young as 2 years old,” Brian Verrier, CEO of OSSIO, said in the release. “Our innovation promises to be a gamechanger for clinicians, kids and parents dealing with the challenge of fixing fractured bones,” Verrier added.
Read more about
Click Here to Manage Email Alerts